Published on October 27, 2009 at 4:09 AM
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that aztreonam for inhalation solution, an investigational product for the treatment of infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF), is scheduled to be reviewed by the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) on December 10, 2009.
In September 2009, the product was granted conditional marketing approval in Canada and Europe under the trade name Cayston® (aztreonam lysine 75 mg powder and solvent for nebuliser solution). Applications for marketing approval of Cayston are also pending in Australia, Switzerland and Turkey.
http://www.gilead.com/